Topcure Pharma

Topcure is an Israel-based biotechnology company specializing in the discovery and development of next-generation epigenetic therapies for cancer. The company utilizes a proprietary platform that integrates advanced epigenetic profiling with computational biology to identify specific disease-driving histone modifications. Topcure's primary focus is the development of highly selective Histone Deacetylase (HDAC) inhibitors designed to overcome the systemic toxicity and limited efficacy associated with traditional pan-HDAC inhibitors. By targeting specific HDAC isoforms, the company aims to provide safer and more effective treatment options for patients with solid tumors and hematological malignancies. Currently in the pre-clinical stage, Topcure is advancing a pipeline of small molecule candidates supported by prominent investors such as aMoon.